About
Technology
Issues
FAQ
Links
Official Page
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.